MX387070B - Metodo para tratar fibrosis hepatica - Google Patents
Metodo para tratar fibrosis hepaticaInfo
- Publication number
- MX387070B MX387070B MX2018014743A MX2018014743A MX387070B MX 387070 B MX387070 B MX 387070B MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 387070 B MX387070 B MX 387070B
- Authority
- MX
- Mexico
- Prior art keywords
- liver fibrosis
- treating liver
- fibrosis
- treating
- t2dm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345086P | 2016-06-03 | 2016-06-03 | |
| PCT/US2017/035628 WO2017210526A1 (en) | 2016-06-03 | 2017-06-02 | Method of treating liver fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014743A MX2018014743A (es) | 2019-04-11 |
| MX387070B true MX387070B (es) | 2025-03-04 |
Family
ID=60479090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014743A MX387070B (es) | 2016-06-03 | 2017-06-02 | Metodo para tratar fibrosis hepatica |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10682344B2 (https=) |
| EP (1) | EP3463350B1 (https=) |
| JP (2) | JP2019517523A (https=) |
| KR (1) | KR102444366B1 (https=) |
| CN (2) | CN115154467B (https=) |
| AU (1) | AU2017274521B2 (https=) |
| BR (1) | BR112018074452A2 (https=) |
| CA (1) | CA3025671C (https=) |
| ES (1) | ES2966111T3 (https=) |
| IL (1) | IL263245B (https=) |
| MX (1) | MX387070B (https=) |
| RU (1) | RU2740902C2 (https=) |
| SG (2) | SG10202012080UA (https=) |
| WO (1) | WO2017210526A1 (https=) |
| ZA (1) | ZA201807992B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| JP2019517523A (ja) * | 2016-06-03 | 2019-06-24 | ケモセントリックス， インコーポレイテッド | 肝線維症を治療する方法 |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CA3043284C (en) * | 2016-11-10 | 2022-06-28 | Galmed Research And Development Ltd. | Treatment for fibrosis |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| JP2020532551A (ja) | 2017-09-03 | 2020-11-12 | アンジオン バイオメディカ コーポレーション | Ｒｈｏ関連コイルドコイルキナーゼ（ＲＯＣＫ）阻害剤としてのビニルヘテロ環 |
| US11292785B2 (en) | 2018-02-02 | 2022-04-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| ES3029158T3 (en) * | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| JP2022514731A (ja) * | 2018-08-14 | 2022-02-15 | アヴォリント | 原発性硬化性胆管炎の処置方法 |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| WO2020117962A1 (en) * | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| PT3911647T (pt) | 2019-01-15 | 2024-03-04 | Gilead Sciences Inc | Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| WO2020181163A1 (en) * | 2019-03-06 | 2020-09-10 | Tobira Therapeutics, Inc. | Lipid-based formulation of cenicriviroc |
| KR20220017917A (ko) | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| CN114245743B (zh) * | 2019-07-30 | 2023-12-08 | Ko生物技术有限公司 | 预防、缓解或治疗肝损伤的组合物和方法 |
| WO2021020923A1 (ko) | 2019-07-30 | 2021-02-04 | 주식회사 고바이오랩 | 간 손상 예방, 개선, 또는 치료용 조성물 및 간 손상 예방, 개선, 또는 치료방법 |
| CN114929214A (zh) * | 2019-11-22 | 2022-08-19 | 阿沃林特有限公司 | Sglt2抑制剂治疗原发性胆汁性胆管炎的用途 |
| CN116942684A (zh) * | 2020-02-20 | 2023-10-27 | 甘莱制药有限公司 | 一种用于治疗脂肪性肝炎的药物组合物及其制备方法 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| JP7411875B2 (ja) * | 2020-10-08 | 2024-01-12 | 株式会社 キュロム・バイオサイエンス | ベータ－ラパコンを有効成分として含む胆汁うっ滞性肝疾患予防又は治療用薬学組成物 |
| CN120899882A (zh) * | 2025-06-16 | 2025-11-07 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | Klb蛋白在制备治疗血吸虫感染的药物上的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0511599A (pt) * | 2004-05-26 | 2008-01-02 | Janssen Pharmaceutica Nv | mercaptoimidazóis como antagonistas receptores de ccr2 |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| DK1838674T3 (da) | 2005-01-14 | 2011-06-14 | Chemocentryx Inc | Heteroarylsulfonamider og CCR2 |
| US8067457B2 (en) * | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| WO2007106797A2 (en) * | 2006-03-14 | 2007-09-20 | Janssen Pharmaceutica, Nv | A method of use for substituted dipiperidine ccr2 antagonists |
| US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| CN101511800B (zh) * | 2006-07-14 | 2013-02-27 | 坎莫森特里克斯公司 | 三唑基苯基苯磺酰胺 |
| US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| JP5306344B2 (ja) | 2007-07-12 | 2013-10-02 | ケモセントリックス， インコーポレイテッド | 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| RU2547595C2 (ru) * | 2008-08-18 | 2015-04-10 | Пфайзер Инк | Антитела против ccr2 |
| ES2674275T3 (es) * | 2009-12-17 | 2018-06-28 | Centrexion Therapeutics Corporation | Antagonistas del receptor CCR2 y usos de los mismos |
| CN103391931A (zh) * | 2011-02-25 | 2013-11-13 | 辉瑞有限公司 | 治疗肝纤维化的方法 |
| MX360979B (es) * | 2011-09-16 | 2018-11-22 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico. |
| US20130303446A1 (en) * | 2012-05-09 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| EP3777863A1 (en) * | 2014-09-12 | 2021-02-17 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| JP2019517523A (ja) * | 2016-06-03 | 2019-06-24 | ケモセントリックス， インコーポレイテッド | 肝線維症を治療する方法 |
-
2017
- 2017-06-02 JP JP2018563453A patent/JP2019517523A/ja not_active Withdrawn
- 2017-06-02 CN CN202210819034.8A patent/CN115154467B/zh active Active
- 2017-06-02 RU RU2018145459A patent/RU2740902C2/ru active
- 2017-06-02 AU AU2017274521A patent/AU2017274521B2/en active Active
- 2017-06-02 MX MX2018014743A patent/MX387070B/es unknown
- 2017-06-02 SG SG10202012080UA patent/SG10202012080UA/en unknown
- 2017-06-02 US US15/612,124 patent/US10682344B2/en active Active
- 2017-06-02 KR KR1020187037797A patent/KR102444366B1/ko active Active
- 2017-06-02 EP EP17807548.7A patent/EP3463350B1/en active Active
- 2017-06-02 CA CA3025671A patent/CA3025671C/en active Active
- 2017-06-02 BR BR112018074452-2A patent/BR112018074452A2/pt not_active Application Discontinuation
- 2017-06-02 WO PCT/US2017/035628 patent/WO2017210526A1/en not_active Ceased
- 2017-06-02 CN CN201780048523.5A patent/CN109475537A/zh active Pending
- 2017-06-02 ES ES17807548T patent/ES2966111T3/es active Active
- 2017-06-02 SG SG11201810602YA patent/SG11201810602YA/en unknown
-
2018
- 2018-11-25 IL IL263245A patent/IL263245B/en unknown
- 2018-11-26 ZA ZA2018/07992A patent/ZA201807992B/en unknown
-
2020
- 2020-05-06 US US16/867,956 patent/US11357760B2/en active Active
-
2022
- 2022-05-11 US US17/662,979 patent/US20220313668A1/en not_active Abandoned
- 2022-11-30 JP JP2022191906A patent/JP7431931B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807992B (en) | Method of treating liver fibrosis | |
| MX2024010201A (es) | Analogos de incretina y sus usos. | |
| MX2025003745A (es) | Analogos de incretina y sus usos | |
| PH12017502359A1 (en) | Glucagon and glp-1 co-agonist compounds | |
| EP4578460A3 (en) | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases | |
| MX2018009170A (es) | Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y esteatohepatitis no alcoholica (nash) y usos de estos. | |
| EP4674862A3 (en) | Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis | |
| SA521430550B1 (ar) | Glp-1r عوامل مساعدة لـ واستخداماتها | |
| MX2021006034A (es) | Agonistas de glp-ir y usos de los mismos. | |
| NZ729678A (en) | Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist | |
| MX2015011756A (es) | Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y la esteatohepatitis no alcoholica (nash) y usos de estos. | |
| EA201692050A1 (ru) | Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита | |
| WO2014106846A3 (en) | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof | |
| EP4596044A3 (en) | Combination therapy of gpr119 agonists and dpp-4 inhibitors | |
| MX2016013575A (es) | Composicion para prevenir o tratar enfermedades del higado graso. | |
| CY1124611T1 (el) | Θεραπειες μη-αλκοολικης στεατοηπατιτιδας (nash) | |
| WO2019221645A3 (en) | Effect of balanites aegyptiaca on the regression of liver fibrosis and cirrhosis | |
| Fortington et al. | Same, same but different… injury and safety promotion in rugby | |
| EP3305267A4 (en) | Fifth generation fu's needle | |
| HK40081415A (en) | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | |
| MATSUMIYA | Urbanization of Ulaanbaatar with reference to Ger Areas | |
| UA41688S (uk) | Логотип «хнеу ім. с. кузнеця» | |
| Okamoto-Mizuno et al. | Effects of different pajamas material on covered area of the body during sleep onset period under mild humid heat exposure | |
| Kohorst | Hand-foot syndrome: case report | |
| TH176687S (th) | อาคารสำเร็จรูป |